中华放射肿瘤学杂志
中華放射腫瘤學雜誌
중화방사종류학잡지
CHINESE JOURNAL OF RADIATION ONCOLOGY
2014年
4期
352-356
,共5页
陈阿龙%陈立新%陈利%胡江%何汇朗%夏景涛
陳阿龍%陳立新%陳利%鬍江%何彙朗%夏景濤
진아룡%진립신%진리%호강%하회랑%하경도
三维影像解剖结构%剂量验证%γ通过率
三維影像解剖結構%劑量驗證%γ通過率
삼유영상해부결구%제량험증%γ통과솔
Anatomic structure of three-dimensional images%Dose verification%γ passing rate
目的 对调强治疗计划进行点、平面和三维剂量验证,在γ通过率基础上具体分析三维解剖结构的剂量误差.方法 分别用指形电离室、Matrixx和ArcCheck测量鼻咽癌和肺癌调强治疗计划各6例,分别比较IMRT和VMAT治疗计划中心点测量剂量偏差,并行成组t检验.比较IMRT和VMAT治疗计划在3%/3 mm、2%/2 mm标准下剂量验证的γ通过率,并行单因素方差分析.使用3DVH来分析患者靶区和OAR的测量剂量偏差.结果 IMRT和VMAT治疗计划中心点剂量平均偏差分别为(0.59±1.31)%和(-1.00±1.03)%,最大偏差均<3%.在3%/3 mm标准下,IMRT计划Matrixx、ArcCheck和3DVH的γ通过率分别为96.28%、97.55%和99.02%,VMAT计划的分别为97.24%、99.67%和98.48%.3DVH系统比较结果表明γ通过率较高情况下(3%/3 mm标准>95%),有2例治疗计划(占总计划16.7%)测量结果中的靶区和OAR的DVH存在明显偏差,包括GTV、脊髓和脑干等在临床指标下的差异.结论 通过γ分析基于三维影像解剖结构来分析测量结果能更有效评估剂量误差对临床计划执行的影响和对临床治疗的损害.
目的 對調彊治療計劃進行點、平麵和三維劑量驗證,在γ通過率基礎上具體分析三維解剖結構的劑量誤差.方法 分彆用指形電離室、Matrixx和ArcCheck測量鼻嚥癌和肺癌調彊治療計劃各6例,分彆比較IMRT和VMAT治療計劃中心點測量劑量偏差,併行成組t檢驗.比較IMRT和VMAT治療計劃在3%/3 mm、2%/2 mm標準下劑量驗證的γ通過率,併行單因素方差分析.使用3DVH來分析患者靶區和OAR的測量劑量偏差.結果 IMRT和VMAT治療計劃中心點劑量平均偏差分彆為(0.59±1.31)%和(-1.00±1.03)%,最大偏差均<3%.在3%/3 mm標準下,IMRT計劃Matrixx、ArcCheck和3DVH的γ通過率分彆為96.28%、97.55%和99.02%,VMAT計劃的分彆為97.24%、99.67%和98.48%.3DVH繫統比較結果錶明γ通過率較高情況下(3%/3 mm標準>95%),有2例治療計劃(佔總計劃16.7%)測量結果中的靶區和OAR的DVH存在明顯偏差,包括GTV、脊髓和腦榦等在臨床指標下的差異.結論 通過γ分析基于三維影像解剖結構來分析測量結果能更有效評估劑量誤差對臨床計劃執行的影響和對臨床治療的損害.
목적 대조강치료계화진행점、평면화삼유제량험증,재γ통과솔기출상구체분석삼유해부결구적제량오차.방법 분별용지형전리실、Matrixx화ArcCheck측량비인암화폐암조강치료계화각6례,분별비교IMRT화VMAT치료계화중심점측량제량편차,병행성조t검험.비교IMRT화VMAT치료계화재3%/3 mm、2%/2 mm표준하제량험증적γ통과솔,병행단인소방차분석.사용3DVH래분석환자파구화OAR적측량제량편차.결과 IMRT화VMAT치료계화중심점제량평균편차분별위(0.59±1.31)%화(-1.00±1.03)%,최대편차균<3%.재3%/3 mm표준하,IMRT계화Matrixx、ArcCheck화3DVH적γ통과솔분별위96.28%、97.55%화99.02%,VMAT계화적분별위97.24%、99.67%화98.48%.3DVH계통비교결과표명γ통과솔교고정황하(3%/3 mm표준>95%),유2례치료계화(점총계화16.7%)측량결과중적파구화OAR적DVH존재명현편차,포괄GTV、척수화뇌간등재림상지표하적차이.결론 통과γ분석기우삼유영상해부결구래분석측량결과능경유효평고제량오차대림상계화집행적영향화대림상치료적손해.
Objective To verify IMRT plans in point,planar and 3D dose,and to concretely analyze the dose differences of 3D anatomic structure based on Gamma passing rate.Methods Thimble ion-chamber,Matrixx and ArcCheck were separately used to measure six nasopharyngeal carcinoma treatment plans and six lung cancer treatment plans.The dose measurement deviation of the center point was compared as well as the Gamma passing rate of dose verification under the criteria of both 3%/3 mm and 2%/2 mm,the group t-test and one-way ANOVA were also proceeded.3DVH system was used to analyze the dose measurement deviation of target volume (TV) and organ at risk (OAR) through DVH.Results For IMRT and VMAT treatment plans,the mean deviation of point dose was (0.59 ± 1.31) % and (-1.00 ± 1.03)% respectively,and the maximum deviation was less than 3%.Under the criterion of 3%/3 mm,the Gamma passing rate measured by Matrixx,ArcCheck and 3DVH for IMRT plans was 96.28%,97.55% and 99.02% respectively,and for VMAT plans,the corresponding results of three different detectors were 97.24%,99.67% and 98.48%.The results analyzed and compared by 3DVH showed that even under the condition of high Gamma pass rate (more than 95% for a Gamma criterion of 3%/3 mm),the DVH metrics of both TV and OAR in two cases (account for 16.7% of the total plan) were significantly different on the clinical parameters,including GTV,spinal cord and brain stem etc.Conclusions The analysis of dose difference of the measurement results based on Gamma pass rate and on anatomic structure of 3D images can more effectively evaluate the influence of dose error to the implementing of clinical plan and the impact to the clinical treatment.